DE602006020881D1 - Enen eigenschaften - Google Patents

Enen eigenschaften

Info

Publication number
DE602006020881D1
DE602006020881D1 DE602006020881T DE602006020881T DE602006020881D1 DE 602006020881 D1 DE602006020881 D1 DE 602006020881D1 DE 602006020881 T DE602006020881 T DE 602006020881T DE 602006020881 T DE602006020881 T DE 602006020881T DE 602006020881 D1 DE602006020881 D1 DE 602006020881D1
Authority
DE
Germany
Prior art keywords
enen
features
present
vegfr
chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006020881T
Other languages
English (en)
Inventor
Kari Alitalo
Tuomas Tammela
Salla Keskitalo
Katri Pajusola
Markku M Jeltsch
Seppo Yla-Herttuala
Terhi Karpanen
Ulf Eriksson
Marko J Uutela
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vegenics Pty Ltd
Original Assignee
Vegenics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vegenics Pty Ltd filed Critical Vegenics Pty Ltd
Publication of DE602006020881D1 publication Critical patent/DE602006020881D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE602006020881T 2005-08-15 2006-08-15 Enen eigenschaften Active DE602006020881D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70822605P 2005-08-15 2005-08-15
PCT/US2006/032012 WO2007022287A2 (en) 2005-08-15 2006-08-15 Modified vegf and pdgf with improved angiogenic properties

Publications (1)

Publication Number Publication Date
DE602006020881D1 true DE602006020881D1 (de) 2011-05-05

Family

ID=37670985

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006020881T Active DE602006020881D1 (de) 2005-08-15 2006-08-15 Enen eigenschaften

Country Status (7)

Country Link
US (2) US8025886B2 (de)
EP (1) EP1919944B1 (de)
AT (1) ATE502956T1 (de)
AU (1) AU2006279462A1 (de)
DE (1) DE602006020881D1 (de)
ES (1) ES2363758T3 (de)
WO (1) WO2007022287A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60131146T2 (de) 2000-02-25 2008-03-06 Ludwig Institute For Cancer Research Material und verfahren die hybridvaskularendothelwachstumfaktoren dns und proteine enthalten und screeningverfahren für modulatoren
ES2380340T3 (es) 2003-12-05 2012-05-10 Northwestern University Anfífilos peptídicos auto-ensamblantes y métodos relacionados para la administración de factores de crecimiento
CN101392026B (zh) * 2008-10-09 2011-11-09 黄岚 用于预防和治疗纤维化类疾病以及肝癌的多肽
US8450271B2 (en) * 2009-04-13 2013-05-28 Northwestern University Peptide-based scaffolds for cartilage regeneration and methods for their use
WO2011154308A1 (en) 2010-06-08 2011-12-15 Proyecto De Biomedicina Cima, S.L. New compositions and cell therapy methods for the treatment of cirrhosis
US20130101628A1 (en) * 2011-04-29 2013-04-25 Northwestern University Novel vegf mimetic peptide-based scaffolds for therapeutic angiogenesis and methods for their use
US20140065110A1 (en) * 2012-08-31 2014-03-06 The Regents Of The University Of California Genetically modified msc and therapeutic methods
US9663564B2 (en) 2013-03-15 2017-05-30 The Regents Of The University Of California Vectors and methods to treat ischemia
US20160331807A1 (en) * 2014-01-21 2016-11-17 University Of Helsinki Therapeutic use of vegfr-3 ligands
EP3478718A4 (de) 2016-07-01 2020-07-29 Paracrine Therapeutics AB Verfahren und zusammensetzungen zur hemmung von pdgf-cc
CN107828819B (zh) * 2017-10-30 2020-11-03 武汉生物工程学院 一种利用ANP或IgANP基因构建重组腺病毒的方法及重组腺病毒和应用
JPWO2019098385A1 (ja) * 2017-11-20 2020-12-24 コニカミノルタ株式会社 薬剤評価方法
CN108774286A (zh) * 2018-06-28 2018-11-09 浙江众意生物科技有限公司 一种vegf-a单克隆抗体及试剂盒
WO2024002271A1 (en) * 2022-06-29 2024-01-04 Tianjin University Pdgf-d prodomain and its mutant and fusion

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4580568A (en) 1984-10-01 1986-04-08 Cook, Incorporated Percutaneous endovascular stent and method for insertion thereof
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5087244A (en) 1989-01-31 1992-02-11 C. R. Bard, Inc. Catheter and method for locally applying medication to the wall of a blood vessel or other body lumen
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5674192A (en) 1990-12-28 1997-10-07 Boston Scientific Corporation Drug delivery
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5328688A (en) 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
IT1242149B (it) 1990-09-27 1994-02-16 Consiglio Nazionale Ricerche Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi
US5849571A (en) 1990-10-10 1998-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Latency active herpes virus promoters and their use
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
DE69326631T2 (de) 1992-03-19 2000-06-08 Medtronic Inc Intraluminales Erweiterungsgerät
US5599352A (en) 1992-03-19 1997-02-04 Medtronic, Inc. Method of making a drug eluting stent
US5879934A (en) 1992-07-31 1999-03-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US5776755A (en) 1992-10-09 1998-07-07 Helsinki University Licensing, Ltd. FLT4, a receptor tyrosine kinase
US5336178A (en) 1992-11-02 1994-08-09 Localmed, Inc. Intravascular catheter with infusion array
US5280670A (en) 1992-11-02 1994-01-25 Tdw Delaware, Inc. Apparatus for repairing a transport pipe
US5661033A (en) 1992-11-25 1997-08-26 The Board Of Trustees Of The Leland Stanford Junior University Gene transfer using herpes virus vectors as a tool for neuroprotection
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
DE4311651A1 (de) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
US5464650A (en) 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
US5834441A (en) 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
DE69433592T2 (de) 1993-11-09 2005-02-10 Targeted Genetics Corp., Seattle Die erzielung hoher titer des rekombinanten aav-vektors
FR2716682B1 (fr) 1994-01-28 1996-04-26 Centre Nat Rech Scient Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations.
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US6403088B1 (en) 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
WO1998033917A1 (en) 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
US6245530B1 (en) 1995-08-01 2001-06-12 Ludwig Institute For Cancer Research Receptor ligand
US6221839B1 (en) 1994-11-14 2001-04-24 Helsinki University Licensing Ltd. Oy FIt4 ligand and methods of use
US6130071A (en) 1997-02-05 2000-10-10 Helsinki University Licensing, Ltd. Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
US5707385A (en) 1994-11-16 1998-01-13 Advanced Cardiovascular Systems, Inc. Drug loaded elastic membrane and method for delivery
US5637113A (en) 1994-12-13 1997-06-10 Advanced Cardiovascular Systems, Inc. Polymer film for wrapping a stent structure
US5792453A (en) 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US5928939A (en) 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
US5607918A (en) 1995-03-01 1997-03-04 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B and DNA coding therefor
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
FR2732357B1 (fr) 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
US5773289A (en) 1995-06-06 1998-06-30 University Of Pittsburgh AAV directed targeted integration
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US5622856A (en) 1995-08-03 1997-04-22 Avigen High efficiency helper system for AAV vector production
ES2239338T5 (es) 1995-09-29 2013-05-31 Vegenics Pty Ltd Genes regulados y sus usos
US5653689A (en) 1995-09-30 1997-08-05 Abacus Design & Development, Inc. Infusion catheter
US5830727A (en) 1995-11-18 1998-11-03 Human Gene Therapy Research Institute Herpes simplex virus amplicon mini-vector gene transfer system
US5785965A (en) 1996-05-15 1998-07-28 The Board Of Trustees Of The Leland Stanford Junior Univ. VEGF gene transfer into endothelial cells for vascular prosthesis
FI100928B (fi) 1996-07-05 1998-03-13 Nokia Telecommunications Oy Tiedonsiirtomenetelmä
ES2242227T5 (es) 1996-07-15 2011-12-09 Chugai Seiyaku Kabushiki Kaisha Nuevo factor de tipo vegf.
CA2263890C (en) 1996-08-23 2013-05-14 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
EP1488761A1 (de) 1996-11-01 2004-12-22 Ark Therapeutics Limited Gerät zur Verabreichung eines Arzneimittels an einem Blutgefäss
US6428965B1 (en) 1997-07-17 2002-08-06 The Johns Hopkins University Screening assays for the interaction of semaphorins and neuropilins
WO1999029861A1 (en) 1997-12-09 1999-06-17 Children's Medical Center Corporation Peptide antagonists of vascular endothelial growth factor
NZ505011A (en) 1997-12-24 2004-12-24 Ludwig Inst Cancer Res Expression vectors and cell lines expressing VEGF-D and method of treating melanomas
ES2389387T3 (es) 1998-03-17 2012-10-25 Genentech, Inc. Polipéptidos homólogos de VEGF y de BMP1
GB9809082D0 (en) 1998-04-28 1998-06-24 Eurogene Limited Delivery device
US6238401B1 (en) 1998-07-31 2001-05-29 Zuli Holdings Ltd. Apparatus and method for selectively positioning a device and manipulating it
CA2344561A1 (en) 1998-09-30 2000-04-06 Ludwig Institute For Cancer Research Platelet-derived growth factor c, dna coding therefor, and uses thereof
US20030211994A1 (en) 1998-09-30 2003-11-13 Ludwig Institute For Cancer Research Composition and method for modulating vasculogenesis or angiogenesis
US20020164687A1 (en) 1998-09-30 2002-11-07 Ulf Eriksson Platelet-derived growth factor C, DNA coding therefor, and uses thereof
CN100340291C (zh) 1998-10-09 2007-10-03 路德维格癌症研究院 F1t4(VEGFR－3)作为肿瘤显像和抗肿瘤治疗的靶
JP2003508009A (ja) 1998-10-19 2003-03-04 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ 新規なニューロピリン／増殖因子結合及びその利用法
WO2000024412A2 (en) 1998-10-26 2000-05-04 Ludwig Institute For Cancer Research Use of vegf-c or vegf-d gene or protein to prevent restenosis
NZ511119A (en) 1998-11-02 2004-04-30 Ludwig Inst Cancer Res Vascular endothelial growth factor-like protein from ORF virus NZ2 binds and activates mammalian VEGF receptor-2
EP1129110B1 (de) 1998-11-10 2009-12-09 Ludwig Institute For Cancer Research Von blutplättchen abstammender wachstumsfaktor d, dafür kodierende dns und deren verwendungen
US7148037B2 (en) 1998-11-10 2006-12-12 Ludwig Institute For Cancer Research Platelet-derived growth factor D, DNA coding therefor, and uses thereof
US6342221B1 (en) 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody conjugate compositions for selectively inhibiting VEGF
DE60131146T2 (de) 2000-02-25 2008-03-06 Ludwig Institute For Cancer Research Material und verfahren die hybridvaskularendothelwachstumfaktoren dns und proteine enthalten und screeningverfahren für modulatoren
WO2001082870A2 (en) 2000-05-03 2001-11-08 Ludwig Institute For Cancer Research A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof
SE0004929D0 (sv) 2000-12-29 2000-12-29 Apbiotech Ab A method for producing liquid chromatography matrices
JP4669984B2 (ja) 2001-01-19 2011-04-13 ベジェニクス リミテッド 腫瘍画像化のターゲットとしてのＦ１ｔ４（ＶＥＧＦＲ−３）および抗腫瘍療法
US20030027751A1 (en) 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
EP1427829A4 (de) 2001-08-31 2005-10-12 Abmaxis Inc Multivalentes proteinkonjugat mit mehreren ligandenbindungsrezeptordomänen
US20030113324A1 (en) 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
US20040214766A1 (en) 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
US6846323B2 (en) 2003-05-15 2005-01-25 Advanced Cardiovascular Systems, Inc. Intravascular stent
WO2005016963A2 (en) 2003-06-12 2005-02-24 Ludwig Institute For Cancer Research Heparin binding veger-3 ligands
US20050043235A1 (en) 2003-06-12 2005-02-24 Kari Alitalo Use of VEGF-C or VEGF-D in reconstructive surgery
US9307006B2 (en) 2012-04-11 2016-04-05 Salesforce.Com, Inc. System and method for synchronizing data objects in a cloud based social networking environment
JP6102573B2 (ja) 2013-06-28 2017-03-29 ブラザー工業株式会社 カートリッジ

Also Published As

Publication number Publication date
AU2006279462A1 (en) 2007-02-22
EP1919944B1 (de) 2011-03-23
EP1919944A2 (de) 2008-05-14
US8025886B2 (en) 2011-09-27
WO2007022287A3 (en) 2007-07-26
ES2363758T3 (es) 2011-08-16
US20120071406A1 (en) 2012-03-22
WO2007022287A2 (en) 2007-02-22
ATE502956T1 (de) 2011-04-15
US20070142282A1 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
DE602006020881D1 (de) Enen eigenschaften
IL263755A (en) Antibodies that bind human protein tyrosine phosphate in the cell and their uses
DK2115003T3 (da) Humane antistoffer mod human delta-lignende ligand 4
CY1113199T1 (el) Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης
DK2215119T3 (da) Monoklonale antistoffer der binder til HGM-CSF og medicinske sammensætninger omfattende de samme.
MY163480A (en) Sclerostin binding agents
HK1253391A1 (zh) 與161p2f10b蛋白結合的抗體和相關分子
MY174493A (en) Binding agents
EA201100694A1 (ru) Антитело к cd38 человека и его применение
DK2358756T4 (da) Humane antistoffer med høj affinitet til PCSK9
EA201100923A1 (ru) Антитела человека против тканевого фактора
DK3597216T3 (da) Humane antistoffer, der binder lymfocytaktiveringsgen-3 (lag-3) og anvendelser deraf
UA112416C2 (uk) Антитіло до fap і способи його застосування
EA201170242A1 (ru) Модифицированные бычьи полипептиды g-csf и их применение
TW200745159A (en) IL-6 binding proteins
MY161679A (en) Polypeptides
DK2185574T3 (da) Antistoffer og relaterede molekyler, der bindes til 24P4C12-proteiner
UA109888C2 (uk) ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
EP1877079A4 (de) Aus pflanzen stammende elastinbindungsproteinliganden und verfahren zur verwendung davon
TN2010000169A1 (en) Molecules and methods for modulating complement component
DK1809328T3 (da) Mannooligosaccharid-sammensætning til kropsfedt-reduktion
BRPI0819092A2 (pt) Evolução direcionada usando proteínas que compreendem aminoácidos não naturais.
EA201290542A1 (ru) Модифицированные свиные соматотропиновые полипептиды и их применение
EA201001711A1 (ru) Смесь связанного триптофана в составе пептидов и связанного триптофана в составе полипептидов
DK3360571T3 (da) Antistoffer, der binder til et intracellulært PRL-1- eller PRL-3-polypeptid